Results 131 to 140 of about 2,329 (147)

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis [PDF]

New England Journal of Medicine, 2021
Background: Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease. Methods: We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of ...
Silvio Danese, Brian G. Feagan
exaly   +3 more sources

Ozanimod for the treatment of relapsing remitting multiple sclerosis

Expert Opinion on Pharmacotherapy, 2018
INTRODUCTION: Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis.
Friedemann Paul, Ludwig Rasche
exaly   +2 more sources

Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS [PDF]

Multiple Sclerosis and Related Disorders, 2021
Brain volume; Multiple sclerosis; OzanimodVolumen cerebral; Esclerosis múltiple; OzanimodVolum cerebral; Esclerosi múltiple; OzanimodBackground Cognitive dysfunction, including slowed cognitive processing speed (CPS), is one of the most disabling ...
Diego Silva, Bruce A C Cree, Jeffrey A Cohen   +2 more
exaly   +2 more sources

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial [PDF]

Multiple Sclerosis Journal, 2022
BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for treatment of relapsing forms of MS. OBJECTIVE: To characterize long-term safety and efficacy of ozanimod.
Diego Silva, Amit Bar-or, Bruce A C Cree
exaly   +2 more sources

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis. [PDF]

Inflammatory Bowel Diseases
This study evaluated pregnancy outcomes in patients with ulcerative colitis, Crohn's disease, or multiple sclerosis and in healthy volunteers treated with ozanimod.
Uma Mahadevan, Giancarlo Comi, Krzysztof Selmaj   +2 more
exaly   +2 more sources

Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies

Clinical Gastroenterology and Hepatology
The drug studied was Ozanimod which is an oral sphingosine-1 -phosphate (S1P) receptor modulator, and was experimented in patient suffering from Ulcerative colitis (UC) who weren’t exposed to biological or Janus Kinase (JAK) inhibitors previously.
Bruce E. Sands, Annkatrin Petersen
exaly   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis

Annals of Pharmacotherapy, 2022
Shubha Bhat
exaly  

Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center

Digestive Diseases and Sciences, 2023
David T Rubin, Nathaniel Aviv Cohen, Joel Pekow   +2 more
exaly  

Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.

Journal of Crohn's and Colitis, 2023
David T Rubin, Bruce E. Sands, Ryan Ungaro   +2 more
exaly